Imipenem-Cilastatin
- Generic Name
- Imipenem-Cilastatin
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
本品适用于：
1.病原菌多重耐药，而对本品呈现敏感的需氧革兰氏阴性杆菌所致的严重感染，包括肺炎克雷伯菌、大肠埃希菌阴沟肠杆菌、产气肠杆菌、柠檬酸菌属、黏质沙雷菌等肠杆菌科细菌、不动杆菌属等所致的败血症、下呼吸道感染、尿路感染、腹腔感染、盆腔感染、骨关节感染、皮肤软组织感染等；用于铜绿假单胞菌所致感染时需注意在使用本品过程中某些菌株可出现耐药，必要时治程中监测药敏；
2.用于对脆弱拟杆菌等厌氧菌与需氧菌混合感染的重症患者；
3.病原菌尚不明的严重感染、免疫缺陷者感染的经验治疗。
由于抽搐等严重中枢神经系统不良反应，本品不用于中枢神经系统感染的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
- Conditions
- Interventions
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 2648
- Registration Number
- NCT06059846
- Locations
- 🇿🇦
Medical facility, Durban, South Africa
🇹🇷Medical Facility, Samsun, Turkey
Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections
- Conditions
- Interventions
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Entasis Therapeutics
- Target Recruit Count
- 80
- Registration Number
- NCT03445195
- Locations
- 🇧🇬
Multiprofile Hospital for Active Teatment (MHAT) and Emergency Medicine - Doverie, Sofia, Bulgaria
🇧🇬Universeity Multiprofile Hospital for Active Teatment, Sofia, Bulgaria
🇧🇬University Multiprofile Hospital for Active Teatment-Clinic of Nephrology, Sofia, Bulgaria
GSK2251052 in Complicated Urinary Tract Infection
- Conditions
- Interventions
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2017-09-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT01381549
- Locations
- 🇪🇸
GSK Investigational Site, Pama de Mallorca, Spain
Complicated Skin and Skin Structure Infections
- Conditions
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1000
- Registration Number
- NCT00619710
To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2008-01-10
- Last Posted Date
- 2012-12-28
- Target Recruit Count
- 274
- Registration Number
- NCT00589693
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.